QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Historical Signal Evaluation of SGLT2 Inhibitors and Diabetic Ketoacidosis

Test your understanding of the concepts covered by Historical Signal Evaluation: SGLT2 Inhibitors and Diabetic Ketoacidosis.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which clinical presentation should most strongly prompt consideration of DKA in a patient receiving an SGLT2 inhibitor?

Glucose of 160 mg/dL with nausea, tachypnoea, high-anion-gap acidosis and elevated ketones Glucose of 160 mg/dL with no symptoms, normal anion gap and no ketones Mild isolated thirst after exercise with normal acid-base findings Asymptomatic hyperglycaemia without ketonaemia or acidosis

Question 2 of 10 Which statement best describes the evidentiary role of euglycaemic or modest-glucose DKA in this signal?

It is proof of causality in every exposed patient It is an important clinical phenotype that supports signal recognition but does not alone prove causality It excludes the presence of metabolic acidosis It demonstrates that glucose measurement is unnecessary

Question 3 of 10 Which metabolic change most directly favours ketogenesis in the proposed SGLT2 inhibitor mechanism?

An increased insulin-to-glucagon ratio A reduced insulin-to-glucagon ratio Complete suppression of lipolysis Increased availability of glucose for systemic metabolism

Question 4 of 10 What did the larger 2020 randomised-trial meta-analysis add to the evidence base?

It showed a statistically detectable increase in DKA risk based on a larger accumulated number of events It showed that DKA occurred only in placebo recipients It eliminated all uncertainty about individual causal mechanisms It demonstrated that the absolute DKA risk was greater than 50% over five years

Question 5 of 10 Which conclusion is most scientifically and regulatorily defensible based on the accumulated evidence?

SGLT2 inhibitors cause DKA independently of patient characteristics or clinical context SGLT2 inhibitors do not increase DKA risk because one early meta-analysis was non-significant SGLT2 inhibitors increase DKA risk, including atypical presentations, with risk modified by insulin reserve and metabolic stress Only spontaneous reports support the association, so no causal conclusion is possible

Question 6 of 10 What is the most appropriate interpretation of the Korean cohort study comparing new SGLT2 inhibitor users with DPP-4 inhibitor users?

It demonstrated a statistically significant increase in DKA hospitalisation It found no statistically significant increase, while still providing useful information about heterogeneity and susceptibility It proved that spontaneous reports were entirely caused by confounding It established that DPP-4 inhibitors cause more DKA than SGLT2 inhibitors in every population

Question 7 of 10 Which factor was identified as increasing DKA risk and is particularly relevant to prevention?

Stable food intake with adequate hydration Sudden reduction or interruption of insulin Routine monitoring of ketones during acute illness Avoidance of excessive alcohol intake

Question 8 of 10 Which statement best reflects the article's position on the mechanism of SGLT2 inhibitor-associated DKA?

One single mechanism has been conclusively demonstrated to explain every case The mechanism is biologically plausible but multifactorial, with some pathways incompletely established Mechanistic evidence is irrelevant once spontaneous reports exist The mechanism is disproven because early clinical trials were statistically negative

Question 9 of 10 Which conclusion best represents a multifactorial causality assessment for an individual case?

The SGLT2 inhibitor must be the sole cause because DKA is a recognised adverse reaction The acute infection must be the sole cause because it is a known precipitant The SGLT2 inhibitor may have contributed to susceptibility in combination with infection, fasting, dehydration and insulin reduction Causality cannot be assessed whenever more than one factor is present

Question 10 of 10 Which pharmacological effect of SGLT2 inhibition is established and directly explains its glucose-lowering action?

Increased pancreatic insulin synthesis Reduced hepatic ketone oxidation Increased urinary glucose excretion Direct inhibition of pancreatic alpha cells

Knowledge Assessment: Historical Signal Evaluation of SGLT2 Inhibitors and Diabetic Ketoacidosis

Cookie Settings